Drugs / MVA-EBO Z
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT02485912 Comparator | Jul 2015 → Jan 2016 | Ebola hemorrhagic fever | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT02451891 Comparator | May 2015 → Aug 2017 | Ebola hemorrhagic fever | University of Oxford | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-EBO-Z | “the viral vector modified vaccinia Ankara virus vectored Ebola Zaire vaccine (MVA-EBO-Z), manufactured rapidly on a new duck cell line either alone or in a heterologous...” PMID 30407513 ↗ Apr 2019 |
| Modality | Vaccine | “viral vector modified vaccinia Ankara virus vectored Ebola Zaire vaccine” PMID 30407513 ↗ Apr 2019 |